The Market for Next-Generation Sequencing and Kalorama Survey of NGS Laboratories

Table of Contents

1: Market Analysis and Report Summary
Overall Sequencing Market Revenues

• • Table 1-1: NGS Sequencing Market, 2018-2023
  • Table 1-2: Estimated Sequencing System Market Revenues, 2018-2023
  • Table 1-3: Estimated Sequencing System Consumable Market Revenues, 2018-2023
  • Table 1-4: Estimated Sequencing System Market Revenues, 2018-2023
  • Figure 1-1: Estimated Shares by Product Type, 2018 (%)
  • Figure 1-2: Forecast Shares by Product Type, 2023 (%)
• Regional Breakout
  • Figure 1-3: Regional Breakout
• Market Share
  • Figure 1-4: Market Share by Vendor

Scope
Methodology
Outline
Demographics

• Regional Distribution of Respondents’ Labs
  • Table 1-5: Regional Distribution of Respondent Labs
  • Figure 1-5: Regional Distribution of Respondent Labs (%)
• Industrial Distribution of Respondents’ Labs
  • Table 1-6: Primary Industry/ Segment Labs Belong To
  • Figure 1-6: Primary Industry/ Segment Labs Belong To (%)
  • Table 1-7: Industry/ Segment(s) Labs Belong To, by Region
  • Table 1-8: Industry/ Segment(s) Labs Belong To, by Region (%)
  • Figure 1-7: Industry/ Segment(s) Labs Belong To, by Region (%)
• Laboratory Function of Respondents’ Labs
  • Table 1-9: Major Function(s) of Respondent Labs
  • Figure 1-8: Major Function(s) of Respondent Labs (%)
  • Table 1-10: Major Function(s) of Labs, by Region
  • Table 1-11: Major Function(s) of Labs, by Region (%)
  • Figure 1-9: Major Function(s) of Labs, by Region (%)
• Distribution by Number of Sequencers
  • Table 1-12: Distribution of Total Sequencers in Labs
  • Figure 1-10: Distribution of Total Sequencers in Labs
  • Table 1-13: Number of Next-Generation Sequencers in Labs
  • Figure 1-11: Number of Next-Generation Sequencers in Labs
  • Table 1-14: Number of ABI Capillary Sequencers in Labs
  • Figure 1-12: Number of ABI Capillary Sequencers in Labs
• Brand(s)/ Types(s) of Sequencers Owned, Overall
  • Table 1-15: Brand(s)/ Type(s) of Sequencers Owned by Labs
  • Table 1-16: Number of a Given Brand / Type in Labs Owning Type, 2019
  • Figure 1-13: Avg. Number of a Given Sequencer in Labs Owning Type, 2019
  • Table 1-17: Number of a Given Brand / Type in Labs Owning Type, 2017
  • Figure 1-14: Avg. Number of a Given Sequencer in Labs Owning Type, 2017
• Library Preparation and Other Automation
  • Table 1-18: Library Preparation and Automation Systems
• Position/ Role of Respondents
  • Table 1-19: Position/ Role of Respondent
  • Figure 1-15: Position/ Role of Respondent (%)

2: System Installations
Overall Installed Base

• Distribution of Sequencer Models
  • Table 2-1: Sequencer Models in Respondents’ Labs
  • Figure 2-1: Sequencer Models in Respondents’ Labs (%)
  • Table 2-2: Installed Base of Labs, by System(s) Owned (# of Systems)
  • Table 2-3: Installed Base of Labs, by System(s) Owned (% of Systems)
  • Figure 2-2: Installed Base of Labs, by System(s) Owned (% of Systems)
  • Table 2-4: Installed Base of Labs, by System(s) Owned (% of Systems)
• Distribution of Number of Sequencers
  • Table 2-5: Distribution of NGS vs. Capillary Systems (# of Labs)
  • Figure 2-3: Distribution of NGS vs. Capillary Systems (# of Labs)
  • Table 2-6: # of NGS Systems by # of Capillary Systems (% of Labs)
  • Figure 2-4: # of NGS Systems by # of Capillary Systems (% of Labs)
  • Table 2-7: # of Capillary Systems by # of NGS Systems (% of Labs)
  • Figure 2-5: # of Capillary Systems by # of NGS Systems (% of Labs)

Installed Base by Region

• Overall Brand/ Type
  • Table 2-8: Number of Systems Installed in Labs, by Region
  • Table 2-9: Sequencer Models in Respondents’ Labs, by Region (# of Systems)
  • Table 2-10: Sequencer Models in Respondents’ Labs, by Region (% of Systems)
  • Figure 2-6: Sequencer Models in Respondents’ Labs, by Region (% of Systems)
• Next-Generation Systems
  • Table 2-11: NGS Models in Respondents’ Labs, by Region (# of Systems)
  • Table 2-12: NGS Models in Respondents’ Labs, by Region (% of Systems)
  • Figure 2-7: NGS Models in Respondents’ Labs, by Region (% of Systems)
• Capillary Systems
  • Table 2-13: Capillary Models in Respondents’ Labs, by Region (# of Systems)
  • Table 2-14: Capillary Models in Respondents’ Labs, by Region (% of Systems)
  • Figure 2-8: Capillary Models in Respondents’ Labs, by Region (% of Systems)

   

Installed Base by Industry Segment

• Overall Brand/ Type
  • Table 2-15: Number of Systems Installed, by Industry/ Segment(s)
  • Table 2-16: Brand / Type of Sequencer Systems Installed, by Industry/ Segment, 2019 (# of Systems)
  • Table 2-17: Brand / Type of Sequencer Systems Installed, by Industry/ Segment, 2019 (% of Systems)
  • Figure 2-9: Brand / Type of Sequencer Systems Installed, by Industry/ Segment, 2017 (% of Systems)
  • Table 2-18: Brand / Type of Sequencer Systems Installed, by Industry/ Segment, 2019 (% of Systems)
  • Figure 2-10: Brand / Type of Sequencer Systems Installed, by Industry/ Segment, 2019 (% of Systems)
  • Table 2-19: Brand / Type of Sequencer Systems Installed, by Industry/ Segment, 2013 (# of Systems)
  • Table 2-20: Brand / Type of Sequencer Systems Installed, by Industry/ Segment, 2013 (% of Systems)
  • Table 2-21: Brand / Type of Sequencer Systems Installed, by Industry/ Segment, 2013 (% of Systems)
• Next-Generation Systems
  • Table 2-22: Number of NGS Systems Installed, by Industry/ Segment
  • Table 2-23: Next-Generation Models in Respondents’ Labs, by Industry/ Segment (# of Systems)
  • Table 2-24: Next-Generation Models in Respondents’ Labs, by Industry/ Segment (% of Systems)
  • Figure 2-11: Next-Generation Models in Respondents’ Labs, by Industry/ Segment (% of Systems)
  • Table 2-25: Next-Generation Models in Respondents’ Labs, by Industry/ Segment (% of Systems)
  • Figure 2-12: Next-Generation Models in Respondents’ Labs, by Industry/ Segment (% of Systems)
• Capillary Systems
  • Table 2-26: Number of Capillary Systems Installed in Labs Owning, by Industry/ Segment

Installed Base by Laboratory Function

• Overall Brand/ Type
  • Table 2-27: Number of Systems Installed by Laboratory Function
  • Table 2-28: Brand / Type of Sequencer System Installed, by Lab Function (# of Systems)
  • Table 2-29: Brand / Type of Sequencer System Installed, by Lab Function (% of Systems)
  • Figure 2-13: Brand / Type of Sequencer System Installed, by Lab Function (% of Systems)
  • Table 2-30: Brand / Type of Sequencer System Installed, by Lab Function (% of Systems)
  • Figure 2-14: Brand / Type of Sequencer System Installed, by Lab Function (% of Systems)
• Next-Generation Systems
  • Table 2-31: Number of NGS Installed in Labs Owning, by Lab Function
  • Table 2-32: NGS Models in Respondents’ Labs, by Lab Function (# of Systems)
  • Table 2-33: NGS Models in Respondents’ Labs, by Lab Function (% of Systems)
  • Figure 2-15: NGS Models in Respondents’ Labs, by Lab Function (% of Systems)
  • Table 2-34: NGS Models in Respondents’ Labs, by Lab Function (% of Systems)
  • Figure 2-16: NGS Models in Respondents’ Labs, by Lab Function (% of Systems)
• Capillary / Gel Systems
  • Table 2-35: Number of Capillary Systems Installed in Labs Owning, by Lab Function

3: Sequencer Applications, Clinical Applications, and Usage Trends
Sequencer Applications and Usage

• Applications Run, Overall and by Brand/ Type
  • Table 3-1: NGS Application Volume by Model (% of Sequencing)
  • Figure 3-1: NGS Application Volume by Model (% of Sequencing)
• Likely Increases in Applications and Volume
  • Table 3-2: Applications Expected to Increase the Most, 2019
  • Figure 3-2: Applications Expected to Increase the Most Overall (%)
  • Table 3-3: Applications Expected to Increase, by NGS Brand Owned (# of Labs)
  • Table 3-4: Applications Expected to Increase, by NGS Brand Owned (% of Labs)
  • Figure 3-3: Applications Expected to Increase, by NGS Brand Owned (% of Labs)
  • Table 3-5: Expected Growth in Sequencing Volume (# of Labs)
  • Table 3-6: Expected Growth in Sequencing Volume (% of Labs)
  • Figure 3-4: Expected Growth in Sequencing Volume (% of Labs)
• Capacity Usage of Systems
  • Table 3-7: Avg. Percentage of Systems’ Capacity Used, by Brand
  • Figure 3-5: Percentage of Systems’ Capacity Used, by Brand
• Outsourcing
  • Table 3-8: Percentage of Sequencing Volume Outsourced
  • Figure 3-6: Percentage of Sequencing Volume Outsourced
  • Table 3-9: Percentage of Sequencing Volume Outsourced, by Region
  • Table 3-10: Percentage of Sequencing Volume Outsourced, by Region
  • Table 3-11: Reasons for Outsourcing
  • Figure 3-7: Reasons for Outsourcing (%)

Clinical Applications

• Sequencing of CLIA Regulated Patient Samples
  • Table 3-12: How Labs Address Sequencing of Regulated Patient Samples (# of Labs)
  • Table 3-13: How Labs Address Sequencing of Regulated Patient Samples (% of Labs)
  • Figure 3-8: How Labs Address Sequencing of Regulated Patient Samples (% of Labs)
• Certification for Regulated Samples
  • Table 3-14: Labs’ Certification for Regulated Patient Samples
  • Figure 3-9: Labs’ Certification for Regulated Patient Samples (%)
  • Table 3-15: Distribution of Samples, Est. 2018 (# of Labs)
  • Table 3-16: Distribution of Samples, Est. 2017 (% of Labs)
  • Figure 3-10: Distribution of Samples, Est. 2018 (% of Labs)
  • Table 3-17: Distribution of Samples, Expected 2019 (# of Labs)
  • Table 3-18: Distribution of Samples, Expected 2019 (% of Labs)
  • Figure 3-11: Distribution of Samples, Expected 2019 (% of Labs)
  • Table 3-19: Proportion of Regulated vs. Non-Regulated Samples (% of Sequencing)
  • Figure 3-12: Proportion of Regulated vs. Non-Regulated Samples, Est. 2018 (% of Sequencing)
  • Figure 3-13: Proportion of Regulated vs. Non-Regulated Samples, Expected 2019 (% of Sequencing)
  • Table 3-20: Proportion of Regulated vs. Non-Regulated Samples (% of Sequencing)
  • Figure 3-14: Proportion of Regulated vs. Non-Regulated Samples, est. 2018 (% of Sequencing)
  • Figure 3-15: Proportion of Regulated vs. Non-Regulated Samples, Expected 2014 (% of Sequencing)
• Sequencers Used or Planned for Patient/ Human Samples
  • Table 3-21: Sequencers Used for Regulated Patient Samples
  • Figure 3-16: Sequencers Used for Regulated Patient Samples (% of Systems)
• Disease/ Therapeutic Areas Where Sequencing Applied
  • Table 3-22: Disease Areas Where Sequencing Applied, NGS (Percentage and Number of Systems)
  • Figure 3-17: Disease Areas Where Sequencing Applied (%)
  • Table 3-23: Regulated Sequencing Expected to Grow Fastest
  • Figure 3-18: Regulated Sequencing Expected to Grow Fastest (% of Labs)
  • Table 3-24: Non-Regulated Patient/ Human Sequencing Expected to Grow Fastest
  • Figure 3-19: Non-Regulated Patient/ Human Sequencing Expected to Grow Fastest
• Challenges for Growth of Clinical Sequencing
  • Table 3-25: Challenges for Growth of Clinical Sequencing

4: Preferences and Evaluations
Key Criteria for Choosing Sequencers

• Overall
  • Table 4-1: Most Important Criteria for Sequencer Purchase
  • Figure 4-1: Most Important Criteria for Sequencer Purchase (%)
• By Next-Generation Systems vs Capillary Systems
  • Table 4-2: Most Important Criteria for Purchases, by Brand Owned
  • Table 4-3: Most Important Criteria for Purchase, by Brand Owned

Changes or Improvements

• • Table 4-4: Feature Most Wanted to Change or Improve
  • Figure 4-2: Feature Most Wanted to Change or Improve (%)

Bottlenecks in Process

• • Table 4-5: Bottlenecks in the NGS Process
  • Figure 4-3: Bottlenecks in the NGS Process (%)

5: Future Purchase Plans
Time-Frame of Purchase Plans

• Overall
  • Table 5-1: Time Frame for Future Purchase
  • Figure 5-1: Time Frame for Future Purchase (%)
• By Brand/ Type Owned
  • Table 5-2: Time Frame for Future Purchase, by Brand Owned (# of Labs)
  • Table 5-3: Time Frame for Future Purchase, by Brand Owned (% of Labs)
• By Laboratory Function
  • Table 5-4: Time Frame for Future Purchase, by Lab Function (# of Labs)
  • Table 5-5: Time Frame for Future Purchase, by Lab Function (% of Labs)
• By Region
  • Table 5-6: Time Frame for Future Purchase, by Region (# of Labs)
  • Table 5-7: Time Frame for Future Purchase, by Region (% of Labs)
  • Figure 5-2: Time Frame for Future Purchase, by Region (% of Labs)

Systems Likely to Consider for Purchase

• Overall
  • Table 5-8: Sequencer Models Likely to Consider, 2019-2020
  • Figure 5-3: Sequencer Models Likely to Consider (% of Labs)
• By Brand/ Type Owned
  • Table 5-9: Sequencer Models Likely to Consider, by Brand/ Type Owned (# of Labs)
  • Table 5-10: Sequencer Models Likely to Consider, by Brand/ Type Owned (% of Labs)
  • Figure 5-4: Sequencer Models Likely to Consider, by Brand/ Type Owned (% of Labs)
• By Industry/ Segment
  • Table 5-11: Sequencer Models Likely to Consider, by Industry/ Segment Owned (# of Labs)
  • Table 5-12: Sequencer Models Likely to Consider, by Industry/ Segment Owned (% of Labs)
• By Laboratory Function
  • Table 5-13: Sequencer Models Likely to Consider, by Lab Function (# of Labs)
  • Table 5-14: Sequencer Models Likely to Consider, by Lab Function (% of Labs)
• By Region
  • Table 5-15: Sequencer Models Likely to Consider, by Region (# of Labs)
  • Table 5-16: Sequencer Models Likely to Consider, by Region (% of Labs)
  • Figure 5-5: Sequencer Models Likely to Consider, by Region (% of Labs)

6: Company Profiles
10X Genomics
BGI Genomics (formerly Beijing Genome Institute)
Illumina

• Key Comment
• Recent Revenue History
• Company Reported Highlights in 2018

Oxford Nanopore
Promega Corporation
QIAGEN N.V.

• Key Comment
• Recent Revenue History
• Tuberculosis
• Molecular Expansion
• Precision Medicine / Companion Diagnostics
• Liquid Biopsy

Roche Diagnostics

• Key Comment
• Revenues

Swift Biosciences
Thermo Fisher Scientific Inc.

• Key Comment
• Recent Revenue History
• Next Generation Sequencing

Appendix: Library Preparation

• Table A-1: Library Preparation Related Systems (% of Systems, Count)
• Figure A-1: Library Preparation Related Systems (% of Systems)
• Table A-2: Library Preparation Related Systems (% of Labs Responding, Count)
• Figure A-2: Library Preparation Related Systems (% of Labs Responding)